Experimental gene therapy yields long term cholesterol reduction
In a human trial, the experimental gene therapy VERVE-102 lowered bad LDL cholesterol levels by up to 62 percent with a single dose. By disabling a targeted liver gene, the therapy maintained reduced cholesterol for a full year without requiring daily medication.
The Blend
In recent clinical tests, an experimental treatment called VERVE-102 successfully cut low-density lipoprotein cholesterol by as much as 62 percent using a single infusion. The genetic approach silences a specific liver gene involved in cholesterol management, maintaining reduced levels in patients for a full twelve months.
High cholesterol is a primary driver of cardiovascular disease worldwide, forcing millions to adhere to daily statin pills or frequent injections. Replacing a lifetime of prescriptions with a one-time genetic tweak could transform preventive cardiology, making treatment vastly more convenient for patients at high risk of heart attacks.
However, critical questions about safety and practical access remain. Scientists must monitor trial participants for several years to ensure that permanently altering liver genetics does not trigger unforeseen side effects. Additionally, even if regulators eventually approve the therapy, it is unclear whether health insurance systems will cover such cutting-edge genetic procedures when low-cost daily medications are already widely available.
Written independently by AI News Smoothie from the reporting listed below. Facts belong to the original publishers. Follow the links for their full coverage.
Ingredients
- ‘An extremely exciting milestone!’: landmark treatment slashes cholesterol by 62% with a single dose | BBC Science Focus Magazine
A single dose of the experimental gene-editing therapy VERVE-102 reduced bad cholesterol levels by up to 62 percent for an entire year in early human testing.